Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 864Lymphoma, T-Cell, Cutaneous 143Uveal Melanoma 96Skin Neoplasms 96Mycosis Fungoides 95Sezary Syndrome 81Carcinoma, Basal Cell 76Neoplasm Metastasis 68Lymphoma 64Lymphoma, Non-Hodgkin 63Keratosis, Actinic 61Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 57Carcinoma, Renal Cell 55Carcinoma, Non-Small-Cell Lung 54Lymphoma, B-Cell, Marginal Zone 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 52Lymphoma, Follicular 52Hodgkin Disease 52Lymphoma, Large-Cell, Immunoblastic 50Carcinoma, Merkel Cell 50Burkitt Lymphoma 49Brain Neoplasms 46Multiple Myeloma 44Lymphoma, Large-Cell, Anaplastic 41Recurrence 40Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40Breast Neoplasms 40

Interventions

3-ingenyl angelate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Melanosis × Dermatologic × Clear all
NCT00375739 2016-01-28

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Peplin

Phase 2 Completed
200 enrolled
Dermatologic

Melanosis, Keratosis, Actinic

NCT00107965 2015-03-25

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Peplin

Phase 2 Completed
60 enrolled
Dermatologic

Melanosis, Keratosis, Actinic

NCT00239135 2015-03-25

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Peplin

Phase 2 Completed
34 enrolled
Dermatologic

Keratosis, Melanosis, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡